Self-report INH adherence measures were reliable and valid in Latino adolescents with latent tuberculosis infection

J Clin Epidemiol. 2005 Jun;58(6):645-8. doi: 10.1016/j.jclinepi.2004.11.022.


Background and objective: To test the reliability and validity of 8-day and 30-day self-report measures of adherence to daily isoniazid (INH) for treatment of latent tuberculosis infection (LTBI).

Methods: Participants were 286 Latino adolescents (ages 13-18, 55.6% male) with LTBI recruited from 10 public middle and high schools in San Diego County. INH adherence was measured monthly for up to 9 months by interview and urine specimens at unannounced visits. Reliability and validity analyses were performed within 5 consecutive months. Reliability was assessed by correlating: (1) 8- and 30-day INH adherence measures within each month; and (2) each of the two adherence measures across months. Validity was assessed by correlating reported measures with biological assays within each month.

Results: Reliability tests yielded significant correlation coefficients (p < .05 to .001), both across measures (r = 0.71-0.93) and across time (r = 0.29-0.64 for 8-day recall; r = 0.32-0.69 for 30-day recall). Validity tests of both adherence measures were also significant (p < .05 to .001): 8-day recall (r(pb) = 0.52-0.72) and 30-day recall (r(pb) = 0.37-0.71).

Conclusion: Results suggest that impromptu recall measures of INH adherence, combined with urine collection, are reliable and valid in Latino adolescents.

Publication types

  • Multicenter Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Validation Study

MeSH terms

  • Adolescent
  • Adolescent Behavior
  • Antitubercular Agents / administration & dosage*
  • Disclosure / standards*
  • Female
  • Hispanic or Latino / psychology*
  • Humans
  • Isoniazid / administration & dosage*
  • Male
  • Patient Compliance*
  • Reproducibility of Results
  • Tuberculosis / drug therapy*


  • Antitubercular Agents
  • Isoniazid